FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
Status:
Completed
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, open label, randomized study investigating two dose titration regimens
of CXA-10 in subjects at least 18 years of age with primary FSGS.
The study will be performed at approximately 25 study centers across the United States of
America (USA). The recruitment period is anticipated to be up to approximately 16 months.
Approximately 30 subjects will be randomized to ensure 26 subjects complete the study. An
optional 9 month open label is available
Phase:
Phase 2
Details
Lead Sponsor:
Complexa, Inc.
Collaborators:
Arkana Labs Kidney Research Network, formerly NephCure Accelerating Cures Institute Medpace, Inc. MicroConstants NephCure Kidney International